GlassScriptPhysician profile
Jung H Lee
NPI 1104933738
$44,828.64
in general payments reported to CMS, 2019-2025
41 companies · $1,661 in 2025
The $1,661 reported for 2025 was more than what 80% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $11K · 2021: $7,625 · 2022: $8,266 · 2023: $1,935 · 2024: $2,291 · 2025: $1,661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,709 · Education: $177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,708.98 |
| Education | $177.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $13,644.97 | 2019-2025 | Jardiance |
| Boston Scientific Corporation | $10,744.25 | 2019-2025 | Watchman Flx, Watchman Access System |
| Lilly USA, LLC | $8,990.15 | 2020-2023 | Mounjaro |
| Actelion Pharmaceuticals US, INC. | $1,982.34 | 2019-2025 | Uptravi, Opsumit |
| E.R. Squibb & Sons, L.L.C. | $1,386.48 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $1,289.32 | 2019-2024 | Xarelto |
| Amgen INC. | $825.25 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $718.22 | 2019-2025 | Farxiga |
| Novo Nordisk INC | $681.03 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $672.13 | 2022-2025 | Winrevair, Verquvo, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $487.21 | 2019-2025 | |
| Pfizer INC. | $398.99 | 2019-2025 | |
| Amarin Pharma, INC. | $314.77 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $293.13 | 2019-2025 | |
| Abiomed | $272.47 | 2022-2024 | Impella |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jung Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.